Antipsychotics

Connecticut continues to block public access to information on homicide investigations, according to the Connecticut News Times, an effort that began with concerns over...

In 2004, a patient was given an experimental antipsychotic called bifeprunox and died of hepatorenal failure nine days later. But the sponsor apparently did not investigate the death for three years. In late 2007 the sponsor issued a safety alert and suspended all bifeprunox studies. This is where things get interesting.

An important study was headlined on MIA this week. The study examined the effectiveness of cognitive behavioral therapy (CBT) to treat the symptoms of people labeled with a diagnosis of schizophrenia and related conditions who had elected to not take neuroleptic drugs.

In "the first randomised trial of cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs", researchers from the U.K. found cognitive...

Over one third of people with bipolar diagnoses admitted to a Rhode Island hospital were on four or more psychiatric medications, says research published...

A Louisiana appeals court has thrown out a $257 million verdict which held Johnson & Johnson liable for deceptive practices in marketing its antipsychotic...

In 1972, prisoners at Holmesburg Prison in Philadelphia were paid $3 to have their eyes held open with clamps and hooks while Johnson & Johnson's baby shampoo was dropped into them. In 2011, mothers of newborns were arrested when their babies tested positive for exposure to cannabis, a false result caused by the use of Johnson & Johnson’s Head-to-Toe Foaming Baby Wash. Young men have undergone mastectomies to remove breasts grown as a result of Johnson & Johnson antipsychotics, which were used as a result of Johnson & Johnson's criminal promotion of its drugs for off-label purposes. And now, Johnson & Johnson has announced the removal of carcinogenic chemicals from their No More Tears baby shampoo.

Consumer Reports affirms that, though the use of antipsychotic drugs to treat conditions not approved by the Food and Drug Administration has increased significantly in the...

Seena Fazel from the University of Oxford Department of Psychiatry reviews The Bitterest Pills: The Troubling Story of Antipsychotic Drugs by Joanna Moncrieff for...

Two pieces of research have been published over the last two years that should prompt a major reorientation of the treatment of schizophrenia and psychosis, and a fundamental reappraisal of the use of antipsychotic drugs in general. Put together, these studies suggest that the standard approach to treating serious mental health problems may cause more harm than good. Long-term treatment with antipsychotic drugs has adverse effects on the brain, and may impair rather than improve chances of recovery for some. Many people ask me how the psychiatric profession has responded to this data. Surely, they think, it must have stimulated a major debate within the profession, and some critical reflection about why it took so long to recognise these worrying effects? Sadly, this does not appear to be happening.

I received the following question from a reader regarding the controversial CAFÉ – Comparisons of Atypicals in First Episode of Psychosis - study. (This was the study in which Dan Markingson committed suicide.) "It appears that there was no head-to-head with a control group taking a placebo pill. Nor was there a control group featuring 'old' types of 'antipsychotic'. If that was the case then it is very poor study . . . what on earth can you hope to show from the data?" I started to write a response, but the subject is complex, and my response became the following article.

Attorneys representing about 300 lawsuits alleging that Risperdal causes enlargement of breast tissue in men have asked a Pennsylvania judge to unseal relevant clinical...

Responding to a letter signed by 175 scholars asking for an inquiry into the death of Dan Markingson at the University of Minnesota, the Faculty Senate voted to investigate clinical research at the university. But the university president says the Markingson case will not be part of the investigation. What is he trying to hide?

Before the early 1990’s the use of antipsychotic medications was largely reserved for adults with severe psychotic disorders; unpleasant involuntary movement disorders (extrapyramidal side-effects) and cardiovascular risks appear to have largely limited their use outside these disorders. The introduction and intense marketing of what seemed to be better tolerated and safer (now proven not to be), second generation atypical antipsychotics (AAPs) such as risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole from the mid 1990’s led to a rapid expansion of antipsychotic medication use for a wide variety of unlicensed conditions and in more diverse clinical populations.

Consumer Reports writes that the number of children prescribed antipsychotics has tripled over the last 10 to 15 years, despite a lack of evidence...

Counsel for ex rel Watson v. King-Vassel - Psychrights' latest effort to show that prescribing medication for children that is not supported by scientific evidence constitutes fraud...

LAW360 reports that a Pennsylvania federal judge has dismissed a lawsuit over a movement disorder attributed to Bristol-Myers' drug Abilify.  The judge held that...

Thirty years ago, the prescription of neuroleptic drugs to children under 14 years of age was almost unheard of. It was rare in adolescents, and even in adults was largely confined to individuals who had been given the label schizophrenic or bipolar. By 1993 about a quarter of 1% of the national childhood population were receiving antipsychotic prescriptions during office visits. The percentage for adolescents was about three quarters of 1%. By 2009, these figures had increased to 1.83% and 3.76% respectively. The devastating effects of these neurotoxic drugs are well known, and it is natural to wonder what forces might be driving this trend.

Law 360 reports that Johnson & Johnson asked a Pennsylvania judge to keep a series of clinical studies related to the drug Risperdal under...

For a scathing, 11-minute overview of the death of Dan Markingson at the University of Minnesota, and new allegations of coercion into psychiatric clinical trials, you can't do much better than this excellent investigative report by Jeff Baillon.

Following Johnson & Johnson's record $2.2 billion settlement for criminal marketing — including $1.4 billion related to its marketing of Risperdal, making it one of the...

Research from London and Taipei finds that neuroleptic malignant syndrome (NMS) is associated with the number of different antipsychotics used (polypharmacy), rather than the overall...

If I had remained med compliant I wouldn’t understand the simple joys of caring about my hygiene and my surroundings. I’ve wanted to write about this for a long time but I’ve not done it and I think it’s because I still have shame around how slovenly I became. I hid it from others fairly well most of the time, but I couldn’t hide it from myself. The fact is the drugs stripped me of some very basic elements of human care. When one doesn’t care about their immediate environment and their bodies, they really just don’t care about themselves. It’s a very painful place to be and yet when it’s caused by drugs it’s all muted and weird and not really who we are at all and so really all that is left is horrible shame.

"My studies in this area lead me to a very uncomfortable conclusion: Our citizens would be far better off if we removed all the psychotropic drugs from the market, as doctors are unable to handle them. It is inescapable that their availability creates more harm than good." - Peter Gøtzsche, MD; Co-founder of the Cochrane Collaboration

A colleague and I have been tracking individuals who elect to reduce their dose of neuroleptic drug. The two year results are presented here.